Michael Ulm, MD, fellow, University of Tennessee Health Science Center, West Cancer Center, discusses the rationale and findings of a trial for postoperative pain management in gynecological cancer. The randomized control study tested celecoxib (Celebrex) and ketorolac (Toradol).

The rationale for the trial, Ulm says, was that a lot of physicians don’t like to use intravenous ketorolac with concerns of postoperative bleeding or acute kidney injury. Researchers were trying to find a safer option that was as, if not more, effective. Celecoxib is a COX-2 inhibitor that avoids some of those adverse events. Randomization was 1:1 for patients who underwent robotic hysterectomy. Ulm says the open hysterectomy arm of the study was closed due to poor accrual.

The results showed equivalent pan scores between the 2 drugs. Patients under celecoxib arms were given a prescription to go home with, and Ulm adds these patients used less narcotics once they were home.

Videos

Michael Ulm, MD, fellow, University of Tennessee Health Science Center, West Cancer Center, discusses the rationale and results of a trial for postoperative pain management in gynecological cancer.

Michael Ulm, MD

Articles

Dr. Ulm on Trial for Postoperative Pain Management in Gynecological Cancer